Major Depressive Disorder
📧 Sign up to get email alerts when something new happens for Major Depressive Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-12-07Clinical Trial Update: Internet Based Cognitive Behavioral Therapy Effects on Depressive Cognitions and Brain Function [NA]
A completed clinical trial on internet-based cognitive behavioral therapy for major depressive disorder, reporting results in 2020.
-
CLINICAL_TRIALS trial_result · 2020-12-02Clinical Trial Update: A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder [Phase 2]
A Phase 2 trial evaluating SAGE-217 for moderate to severe major depressive disorder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-01Clinical Trial Update: NMDA Modulation in Major Depressive Disorder in Late- Life [Phase 2]
Phase 2 trial update on NMDA modulation for major depressive disorder in late life has completed.
-
FDA approval · 2020-11-30FDA Approved: BUPROPION HYDROCHLORIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' generic Bupropion hydrochloride under an original application.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: Efficacy of Resveratrol in Depression [Phase 4]
Phase 4 clinical trial update on resveratrol for depression; study completed with posted results.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-17Clinical Trial Update: Intervening Early With Neglected Children [Phase 1, Phase 2]
A mixed Phase 1/Phase 2 clinical trial update titled Intervening Early With Neglected Children investigating Conduct Disorder and ADHD (with…
-
CLINICAL_TRIALS trial_result · 2020-11-16Clinical Trial Update: Cognitive Behavioral Therapy for Adherence in Patients With Type 2 Diabetes [NA]
A completed clinical trial evaluating cognitive behavioral therapy to improve adherence in patients with type 2 diabetes and depression.
-
FDA approval · 2020-11-13FDA Approved: TRINTELLIX — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for TRINTELLIX (vortioxetine) by Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: The UTHealth Ketamine Project [Phase 2]
Phase 2 trial update for the UTHealth Ketamine Project in treatment-resistant depression and major depressive disorder (terminated with resu…
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness [NA]
Clinical trial update on a mobile texting intervention for people with serious mental illness has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: PEER Interactive to Inform the Prescription of Medications [Phase 4]
Phase 4 clinical trial update involving PEER Interactive to inform prescription of medications for depression.
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: The ISLAND Study: InSuLa Assessed Needs for Depression [Phase 4]
Phase 4 clinical trial assessing depression treatment in the ISLAND study; results posted after completion.
-
FDA approval · 2020-11-04FDA Approved: MIRTAZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Mirtazapine from Mylan Pharmaceuticals (ANDA 076122).
-
FDA approval · 2020-11-03FDA Approved: VENLAFAXINE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for venlafaxine hydrochloride (generic) under ANDA076565, enabling it…
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment [Phase 4]
Phase 4 trial evaluating reward processing in major depressive disorder before and after desvenlafaxine treatment.
-
FDA approval · 2020-10-30FDA Approved: QUETIAPINE EXTENDED RELEASE — Supplemental Application (ACI Healthcare USA, Inc.)
FDA approves a supplemental application for a generic quetiapine extended-release product by ACI Healthcare USA, Inc.
-
CLINICAL_TRIALS trial_result · 2020-10-30Clinical Trial Update: Study to Explore the Effective Doses and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets [Phase 2]
Phase 2 trial assessing effective doses, safety, and efficacy of Hypidone Hydrochloride Tablets for major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2020-10-30Clinical Trial Update: To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD [Phase 1, Phase 2]
Clinical trial update for Hypidone Hydrochloride Tablets in major depressive disorder, spanning Phase 1 and Phase 2, status completed.
-
CLINICAL_TRIALS trial_result · 2020-10-29Clinical Trial Update: 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide [Phase 3]
This ClinicalTrials.gov update reports the completion of a Phase 3 study evaluating intranasal esketamine plus standard of care for rapid re…
-
FDA approval · 2020-10-29FDA Approved: BUPROPION HYDROCHLORIDE — Supplemental Application (CIPLA USA INC.,)
FDA approved a supplemental application for BUPROPION HYDROCHLORIDE from CIPLA USA INC., updating the existing approved product.
-
CLINICAL_TRIALS trial_result · 2020-10-28Clinical Trial Update: Intra-nasal vs. Intra-venous Ketamine Administration [Phase 4]
Phase 4 trial comparing intra-nasal versus intra-venous ketamine administration in adults with major depressive disorder has completed.
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: Study to Treat Major Depressive Disorder With a New Medication [Phase 2]
Phase 2 trial update for a new medication targeting major depressive disorder with symptoms including anhedonia; study completed with posted…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: Desvenlafaxine in Opioid-Dependent Patients [Phase 4]
Phase 4 trial update involving desvenlafaxine in patients with depression and opioid dependence (including methadone treatment) has complete…
-
FDA approval · 2020-10-21FDA Approved: VENLAFAXINE HYDROCHLORIDE — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the generic venlafaxine hydrochloride (venlafaxine) under Original Application for the treatment of major depressive disorder, …
-
CLINICAL_TRIALS trial_result · 2020-10-20Clinical Trial Update: Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder [Phase 2]
Phase 2 trial investigating tocilizumab augmentation in treatment-refractory major depressive disorder; study terminated with results posted…